Molecular Pathology:-
Introduction:-
A developing field of pathology called
molecular pathology is concerned with studying and diagnosing disease by
looking at molecules in organs, tissues, or physiological fluids. It is
multidisciplinary in character and mostly concentrates on the microscopic
features of illness.
Molecular and
genetic approaches to the diagnosis and classification of human diseases, the
design and validation of predictive biomarkers for treatment response and
disease progression, and the propensity of people with different genetic
make-ups to develop disorders are all included in this scientific field.
Quantitative
polymerase chain reaction (qPCR), multiplex PCR, DNA microarray, in situ
hybridization, in situ RNA sequencing, DNA sequencing, antibody-based
immunofluorescence tissue assays, molecular profiling of pathogens, and
analysis of bacterial genes for antimicrobial
resistance are just a few of the many techniques available.
Molecular pathological epidemiology (MPE):-
Which stands for
integrative molecular biologic and population health research, is an
interdisciplinary field that resulted from the fusion of "molecular
pathology" and "epidemiology."
Molecular
pathological epidemiology (MPE, sometimes known as molecular pathologic
epidemiology) is a field that combines pathology and epidemiology. Epidemiology
of molecular pathology and disease heterogeneity is how it is described. MPE
seeks to accomplish this goal at the molecular, individual, and population
levels. Pathology and epidemiology have the same goal of investigating the
genesis of disease. Typically, tissue pathology resources and data from ongoing
epidemiology investigations are used in MPE. MPE and conventional-type
molecular epidemiology that makes use of standard disease nomenclature systems
are both commonly referred to as molecular epidemiology.
A disease's course:-
The evolution of
diseases is an intrinsically heterogeneous process,
according to data from The Cancer Genome Atlas studies. The uniqueness of the
exposome and its influence on the molecular pathologic process result in a
unique disease process for each patient (the "unique illness
principle"). Clinical medicine has embraced this idea, along with
precision medicine and individualised treatment.
Methodology:-
In MPE,
researchers analyse the
connections between exposures (such as environmental, nutritional,
lifestyle, and genetic factors), changes to cellular or extracellular molecules
(disease molecular signatures), and the evolution and progression of disease.
The genome, methylome, epigenome, metabolome, transcriptome, proteome,
microbiome, immunity, and interactome can all be examined by researchers.
Certain molecular signatures can be used to associate a suspected risk factor.
Using extensive
population-based data and MPE
research, a novel biomarker with potential clinical relevance can be identified
(e.g., PIK3CA mutation in colorectal cancer to select patients for aspirin
therapy). The MPE approach, also known as the "GWAS-MPE strategy,"
can be applied after a genome-wide association study (GWAS). Through the use of
molecular pathology, surrogate histopathology, or immunohistochemistry
examination of sick tissues and cells within GWAS, detailed disease endpoint
phenotyping can be carried out.
Potential risk
alleles discovered by GWAS can also be investigated using molecular pathology
studies on sick tissues as an alternate strategy. This GWAS-MPE technique can
provide more accurate impact estimates, even greater effects, for particular
molecular subtypes of the disease, as well as pathogenesis-related insights by
connecting genetic variants to molecular
pathologic markers of the disease.
History:-
Analysis of risk
variables (such as smoking) and molecular pathology findings was how MPE first
got started (e.g., KRAS G12C oncogene mutations in lung carcinoma).
Throughout the
1990s and the beginning
of the 2000s, studies to look at the connection between an exposure and
molecular pathological markers of disease (especially cancer) proliferated.
There aren't
enough interdisciplinary experts, standardised procedures, or training
programmes for using molecular pathology in epidemiology. Because MPE studies
variability in an outcome variable, new conceptual frameworks and procedures
(epidemiological approach) were necessary for MPE research.
2010 saw the introduction
of the phrase "molecular pathological epidemiology" by Shuji Ogino
and Meir Stampfer. Following 2010, certain MPE concepts were developed. The MPE
paradigm has been discussed at international conferences and is used widely
throughout the world.
Contact Us:
Email Us: pathology@universeconferences.com
Recent Blog Posts:
Comments
Post a Comment